Boston Scientific (BSX) Other Accumulated Expenses (2009 - 2026)

Boston Scientific has disclosed Other Accumulated Expenses across 18 years of filings, most recently posting $875.0 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $875.0 million, down 5.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $875.0 million (down 5.2% YoY), and the FY2025 annual result was $795.0 million, down 10.37% from the prior year.
• Other Accumulated Expenses came in at $875.0 million for Q1 2026 at Boston Scientific, up from $795.0 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.0 billion in Q1 2022 to a low of $752.0 million in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $862.0 million (2025), against an average of $855.1 million.
• Across the five-year window, Other Accumulated Expenses soared 46.67% in 2022 and declined 23.89% in 2023, its largest moves.
• Boston Scientific's Other Accumulated Expenses stood at $761.0 million in 2022, then gained by 6.96% to $814.0 million in 2023, then advanced by 8.97% to $887.0 million in 2024, then retreated by 10.37% to $795.0 million in 2025, then advanced by 10.06% to $875.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $875.0 million (Q1 2026), $795.0 million (Q4 2025), and $862.0 million (Q3 2025), per Business Quant data.